Abbott Laboratoriesvs.Natera
ABT vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 3.0× larger than Natera by market cap; year to date, Natera leads (+72.7% vs −21.2%).
Side by side
| ABT | NTRA | |
|---|---|---|
| Market cap | $168B | $55.6B |
| Price | $98.49 | $390.79 |
| Today | −0.2% | −1.2% |
| Return YTD | −21.2% | +72.7% |
| Return 1Y | −25.8% | +134.7% |
| Since June 26, 2026 | +4.6% | +49.2% |
| P/E | 31.0 | — |
| P/S | 3.6 | 20.5 |
| P/B | 3.3 | 30.5 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More ABT & NTRA comparisons
Other head-to-heads in the Diagnostics segment.